|
|
||||||||
-synthase-deficient
mice
1 Veterans Affairs Medical Center, Iowa City 52246; Departments of 2 Internal Medicine and 3 Pharmacology, University of Iowa College of Medicine, Iowa City, Iowa 52242; 4 Department of Pathology, University of North Carolina, Chapel Hill, North Carolina 27599; and 5 Oregon Regional Primate Research Center, Beaverton, Oregon 97006
| |
ABSTRACT |
|---|
|
|
|---|
Hyperhomocysteinemia
is a risk factor for stroke, myocardial infarction, and venous
thrombosis. Moderate hyperhomocysteinemia is associated with impaired
endothelial function, but the mechanisms responsible for endothelial
dysfunction in hyperhomocysteinemia are poorly understood. We have used
genetic and dietary approaches to produce hyperhomocysteinemia in mice.
Heterozygous cystathionine
-synthase-deficient mice (CBS +/
),
which have a selective defect in homocysteine transsulfuration, and
wild-type (CBS +/+) littermates were fed either a control diet or a
diet that is relatively deficient in folic acid for 6 wk. Plasma total
homocysteine was 5.3 ± 0.7 µM in CBS +/+ mice and 6.4 ± 0.6 µM in CBS +/
mice (P = 0.3) given the control
diet. Plasma total homocysteine was 11.6 ± 4.5 µM in CBS +/+
mice and 25.1 ± 3.2 µM in CBS +/
mice (P = 0.004) given a low-folate diet. In mice fed the control diet,
relaxation of aortic rings in response to the endothelium-dependent
vasodilator acetylcholine did not differ significantly between CBS +/+
mice and CBS +/
mice. In contrast, in mice fed a low-folate diet, maximal relaxation to acetylcholine was markedly impaired in CBS +/
mice (58 ± 9%) compared with CBS +/+ mice (84 ± 4%)
(P = 0.01). No differences in relaxation to the
endothelium-independent vasodilator sodium nitroprusside were observed
among the four groups of mice. These data indicate that CBS-deficient
mice are predisposed to hyperhomocysteinemia during dietary folate
deficiency, and moderate hyperhomocysteinemia is associated with marked
impairment of endothelial function in mice.
acetylcholine; atherosclerosis; endothelium; homocysteine; thrombomodulin
| |
INTRODUCTION |
|---|
|
|
|---|
HYPERHOMOCYSTEINEMIA is associated with increased risk for stroke, myocardial infarction, and venous thrombosis (3, 7, 27). Previous studies in humans and nonhuman primates have demonstrated that experimental moderate hyperhomocysteinemia (plasma total homocysteine concentration of 10-30 µM) produces endothelial dysfunction, including impaired endothelium-dependent vasodilatation (1, 4, 5, 16, 25, 38) and decreased thrombomodulin anticoagulant activity (22, 25). However, the precise mechanisms by which hyperhomocysteinemia predisposes blood vessels to endothelial dysfunction are poorly understood (20).
Several potential mechanisms have been proposed to explain endothelial dysfunction during hyperhomocysteinemia, including direct endothelial injury due to increased oxidative stress (26, 30), homocysteine-induced reductive stress leading to altered gene expression (33), altered cellular methylation (19), and direct effects on coagulation or fibrinolysis (13, 21). Experimental evidence for some of these proposed mechanisms has been obtained from studies of endothelial cells exposed to exogenous homocysteine in vitro, but these mechanisms have not been examined definitively using a physiologically relevant model of hyperhomocysteinemia in vivo.
One approach to examine mechanisms of endothelial dysfunction in vivo
is to study effects of hyperhomocysteinemia in genetically altered
strains of mice. The first well-characterized genetic model of
hyperhomocysteinemia in mice was developed by Watanabe et al.
(39), who created a targeted deletion of the cystathionine
-synthase (CBS) gene by homologous recombination. Because CBS is the
rate-limiting enzyme in homocysteine transsulfuration
(10), CBS-deficient mice are predisposed to
hyperhomocysteinemia. When homozygous CBS-deficient mice (CBS
/
)
are fed a standard laboratory diet, they develop markedly elevated
levels of plasma total homocysteine (~200 µM), and they also
exhibit growth retardation, hepatic dysfunction, and shortened
survival. Because of the severity of the phenotype, however, CBS
/
mice may have limited utility for investigation of specific effects of
hyperhomocysteinemia on endothelial function. In contrast, heterozygous
CBS-deficient mice (CBS +/
) may be a more useful experimental model
of hyperhomocysteinemia because they have normal growth and viability
despite mildly elevated concentrations of plasma total homocysteine
(6-15 µM) (39). Concentrations of plasma total
homocysteine in CBS +/
mice are quite similar to those in humans with
heterozygous CBS deficiency (31), which suggests that
partial genetic impairment of homocysteine transsulfuration produces
similar effects on homocysteine metabolism in humans and mice.
CBS +/
mice do not develop spontaneous atherosclerotic or other
vascular lesions when fed a normal diet (39), but a recent preliminary report suggests that they may have subtle abnormalities of
endothelial vasomotor function (6). It is uncertain,
however, whether this genetic model will be useful to dissect
mechanisms of endothelial dysfunction in hyperhomocysteinemia. Because
homocysteine metabolism is influenced by both genetic and dietary
factors (27), we suspected that the vascular phenotype of
CBS-deficient mice may vary depending on dietary conditions. Therefore,
we tested the hypothesis that CBS +/
mice are predisposed to
hyperhomocysteinemia and endothelial dysfunction by dietary folate
deficiency, which impairs homocysteine remethylation. Our results
demonstrate that dietary folate deficiency elevates plasma total
homocysteine concentration and produces marked endothelial dysfunction
in CBS +/
mice.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Mice and experimental protocol.
To minimize the potential influence of differences in genetic
background, CBS-deficient mice (39) were crossbred to
C57BL/6J mice (The Jackson Laboratory) for at least eight generations, and comparisons were performed between heterozygous CBS-deficient (CBS
+/
) mice and wild-type (CBS +/+) littermates. Genotyping for the
targeted CBS allele was performed by polymerase chain reaction
(39). At the time of weaning, mice were fed either a
control diet that contains 0.75 mg folic acid/100 g (LM-485, Harlan
Teklad) or a diet that is relatively deficient in folic acid (0.15 mg/100 g) for 6 wk. The low-folate diet contained succinylsulfathiazole (0.1 mg/100 g) to decrease folate availability from intestinal bacteria. At 9-10 wk of age, mice were euthanized with
pentobarbital sodium (75 mg ip), plasma was collected into EDTA (final
concentration 5-10 mM) for measurement of total homocysteine and
folate, and the thoracic aorta was removed for ex vivo studies. The
experimental protocol was approved by the University of Iowa and
Veterans Affairs Animal Care and Use Committees.
Vascular responses.
After removal of loose connective tissue, the proximal aorta was cut
into multiple 3- to 4-mm rings. Rings were suspended in an organ
chamber containing oxygenated Krebs buffer maintained at 37°C and
connected to a force transducer to measure isometric tension
(contraction and relaxation) (2, 25).
Contraction dose-response curves were generated by cumulative additions
of the thromboxane A2 analog U-46619 (0.03-3 µg/ml).
Other rings were contracted submaximally using U-46619, and relaxation
dose-response curves were generated by cumulative additions of the
endothelium-dependent vasodilator acetylcholine (10
8 to
10
5 M) or the endothelium-independent vasodilator sodium
nitroprusside (10
8 to 10
5 M). We have used
these methods previously in mouse vessels and demonstrated that
responses to acetylcholine are mediated by nitric oxide
(2, 9, 18).
Aortic thrombomodulin activity. Thrombomodulin activity (thrombomodulin-dependent activation of protein C) was measured using a modification of a two-stage assay described previously (25). In the first stage, 0.15 µM human protein C (generously provided by Dr. Hans Peter Schwarz, Immuno) and 2.6 nM human thrombin (Enzyme Research Laboratories) were incubated for 30 min at 37°C with rings of proximal thoracic aorta 1.0 mm in length. In the second stage, the amidolytic activity of activated protein C was measured spectrophotometrically using the chromogenic substrate S-2366 (Kabi Pharmacia Hepar). Replicate assays were performed with four to five rings from each aorta. Reference curves were generated using rabbit lung thrombomodulin (American Diagnostica). One unit of activity was defined as the amount of activated protein C generated in the presence of 1.0 nM rabbit thrombomodulin. This assay detects thrombomodulin activity on the luminal endothelium, because denudation of the vessels decreased protein C activation by >90%.
Plasma assays. Plasma total homocysteine concentration was measured by high-performance liquid chromatography and electrochemical detection as described previously (28, 29). Total homocysteine was defined as the amount of homocysteine obtained after treatment of the sample with a reducing agent that converts free and bound disulfides into their respective thiols (32). Hyperhomocysteinemia was defined as the elevation of plasma total homocysteine. Plasma levels of folate were measured by an automated chemiluminescence immunoassay (Chiron Diagnostics ACS:180).
Statistical analysis. Comparisons were performed using the unpaired two-tailed Student's t-test. A value of P < 0.05 was used to define statistical significance. Values are reported as means ± SE.
| |
RESULTS |
|---|
|
|
|---|
Experimental hyperhomocysteinemia.
Experimental hyperhomocysteinemia was produced by combining dietary
folate deficiency with genetic deficiency of CBS. Deficiency of folate
was used to limit homocysteine remethylation, and heterozygous CBS
deficiency was employed to examine effects of impaired homocysteine transsulfuration (Fig. 1). Beginning at
the time of weaning (about 3 wk of age), CBS +/
and CBS +/+
littermates were fed either control diet or low-folate diet for
6-7 wk. In mice fed control diet, plasma total homocysteine
concentration did not differ significantly between CBS +/
and CBS +/+
mice (Table 1). In mice fed low-folate diet, plasma total homocysteine concentration was markedly elevated in
CBS +/
mice compared with CBS +/+ mice (P = 0.004)
(Table 1). Plasma concentrations of folate were ~50% lower in CBS
+/+ or CBS +/
mice fed low-folate diet compared with CBS +/+ or CBS +/
mice fed control diet (P = 0.001) (Table 1).
|
|
Vasomotor responses.
The endothelium-dependent vasodilator acetylcholine and the
endothelium-independent vasodilator nitroprusside each produced dose-dependent relaxation of aortic rings from all mice. In mice fed
control diet, no differences in relaxation to acetylcholine were
observed between CBS +/+ and CBS +/
mice (Fig.
2A). Maximal relaxation to the
highest dose of acetylcholine was 81 ± 4% in CBS +/+ mice and
75 ± 5% in CBS +/
mice (P = 0.4). Similarly, no differences in relaxation to nitroprusside (Fig.
3B) or contraction to the
thromboxane A2 analog U-46619 (Fig. 2C) were
observed between CBS +/+ and CBS +/
mice fed control diet.
|
|
mice compared with CBS +/+ mice (Fig.
3A). Maximal relaxation to acetylcholine was 58 ± 9%
in CBS +/
mice compared with a relaxation of 84 ± 4% in CBS
+/+ mice (P = 0.01). Relaxation to nitroprusside did
not differ significantly between CBS +/+ and CBS +/
mice fed
low-folate diet (Fig. 3B), although maximal relaxation to
nitroprusside tended to be lower in CBS +/
mice than in CBS +/+ mice
(P = 0.14). No differences in contraction to U-46619
were observed between CBS +/+ and CBS +/
mice fed low-folate diet
(Fig. 3C).
Aortic thrombomodulin activity.
Previous studies in monkeys suggested that diet-induced
hyperhomocysteinemia was associated with impaired
thrombomodulin-dependent activation of anticoagulant protein C in the
aorta and carotid artery (25). Therefore, we measured
thrombomodulin activity ex vivo in aortas obtained from mice fed
control or low-folate diets. No differences in aortic thrombomodulin
activity were observed between CBS +/+ and CBS +/
mice fed either
control or low-folate diets (Fig. 4).
|
| |
DISCUSSION |
|---|
|
|
|---|
In this study, we have combined genetic and dietary approaches to
produce moderate hyperhomocysteinemia in mice. We found that dietary
folate deficiency produced a greater elevation in plasma total
homocysteine concentration in CBS +/
mice than in CBS +/+ mice.
Endothelial vasomotor dysfunction was observed only in mice with a
combined defect in homocysteine remethylation (produced by dietary
folate deficiency) and homocysteine transsulfuration (produced by
heterozygous deficiency of CBS).
The mean plasma total homocysteine concentration in CBS +/
mice fed
the low-folate diet was 25 µM, which is similar to plasma total
homocysteine levels obtained after oral methionine loading in humans
(12). Several recent studies have demonstrated that methionine loading produces acute impairment of endothelium-dependent relaxation of conduit or resistance vessels in human subjects (1, 4, 5, 16,
38). In each of these studies, acute impairment of
endothelial function was detected within 2-8 h after ingestion of
methionine, which increased plasma total homocysteine concentrations to
20-30 µM. Our observation that responses to the
endothelium-dependent vasodilator acetylcholine were impaired in CBS
+/
mice that were fed the low-folate diet indicates that experimental
hyperhomocysteinemia also produces adverse effects on endothelial
function in mice. These findings are consistent with our previous
studies in which endothelial vasomotor dysfunction was detected in
cynomolgus monkeys with diet-induced hyperhomocysteinemia (25). Because impaired vasomotor responses were observed
only in the group of mice with the highest levels of plasma total
homocysteine, it cannot be determined from these data whether the CBS
+/
genotype sensitizes to vascular function independently of its
effects on plasma total homocysteine concentration.
In contrast to the marked endothelial vasomotor dysfunction observed in
CBS +/
mice fed low-folate diet, no impairment of endothelial
function was detected in CBS +/+ mice fed low-folate diet, even though
these mice had mildly elevated concentrations of plasma total
homocysteine (~12 µM). This finding in mice differs somewhat from
previous findings in cynomolgus monkeys, in which endothelial
dysfunction was detected in the presence of very mild elevation of
plasma concentrations of total homocysteine (~11 µM)
(25). Thus it appears that higher concentrations of plasma total homocysteine may be required to produce endothelial vasomotor dysfunction in mice than in monkeys. This apparent difference in
concentration dependence may be partly due to the fact that fasting
homocysteine levels were measured in monkeys, whereas nonfasting levels
were measured in mice. It also is possible that the differential
sensitivity to hyperhomocysteinemia between monkeys and mice is due to
species-specific differences in antioxidant mechanisms
(35) or other mechanisms that regulate
endothelium-dependent relaxation. Despite these differences in
concentration dependence, it is clear that endothelial vasomotor
dysfunction is a consistent and reproducible consequence of
hyperhomocysteinemia in experimental animals and humans. Previous
studies using pharmacological approaches and gene-targeting have
demonstrated that relaxation of the mouse aorta in response to
acetylcholine is mediated by nitric oxide produced by endothelial
nitric oxide synthase (15, 17,
18). These ex vivo findings are consistent with earlier
observations that homocysteine decreases bioavailability of nitric
oxide in cultured endothelial cells (36, 37).
In addition to preventing pathological vasoconstriction,
endothelium-derived nitric oxide also inhibits platelet aggregation and
leukocyte adhesion. Thus decreased bioavailability of nitric oxide is a
plausible mechanism for increased risk of thrombosis and
atherosclerosis in hyperhomocysteinemia.
If oxidative inactivation of endogenous endothelium-derived
nitric oxide is a major mechanism for endothelial dysfunction in
experimental hyperhomocysteinemia (26), one might also
expect to see abnormal vascular responses to exogenous
nitrovasodilators, such as nitroprusside. We observed that CBS +/
and
CBS +/+ mice tended to differ in responses to nitroprusside when they
were fed the low-folate diet (Fig. 4B). Although this
difference did not reach statistical significance, the observation is
consistent with previous findings that vasodilator responses to
nitroprusside are modestly impaired in monkeys with diet-induced
hyperhomocysteinemia or hypercholesterolemia (8,
22, 25). These observations suggest that
hyperhomocysteinemia may lead to oxidative inactivation of nitric oxide
derived from both exogenous and endogenous sources.
In addition to producing impairment of endothelial vasomotor function,
hyperhomocysteinemia may adversely affect anticoagulant properties of
endothelium. Thrombomodulin is an endothelial surface protein that
functions as a critical cofactor for activation of anticoagulant
protein C (24). The thrombomodulin/protein C system and
endothelium-dependent regulation of vasomotor tone are two distinct but
complementary properties of endothelium that may protect vessels from
thrombotic complications of vascular disease. Thrombomodulin-dependent
activation of protein C can be inhibited by exogenous homocysteine in
cultured human endothelial cells (14, 23,
34), and monkeys with diet-induced hyperhomocysteinemia have decreased thrombomodulin activity in the aorta and carotid artery
(25). We did not, however, detect any differences in aortic thrombomodulin activity between CBS +/+ and CBS +/
mice fed
either control or low-folate diets. These results imply that human,
macaque, and murine thrombomodulin may differ in sensitivity to
hyperhomocysteinemia. In this regard, it is noteworthy that human
thrombomodulin contains a critical methionine residue that is sensitive
to oxidation, which results in loss of thrombomodulin activity
(11). Although murine thrombomodulin also contains a
methionine residue in this position, it is not known whether its
activity is altered by oxidative stress.
In summary, a folate-deficient diet produces hyperhomocysteinemia and impaired endothelial function in heterozygous CBS-deficient mice. Because of the increasing use of transgenic and gene-targeting techniques in mice, the availability of this murine model should facilitate future studies of mechanisms of vascular dysfunction in hyperhomocysteinemia.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Kara Brown for technical assistance.
| |
FOOTNOTES |
|---|
This work was supported by the Office of Research and Development, Department of Veterans Affairs, National Institutes of Health Grants HL-07344, DK-25295, and NS-24621, and the Roy J. Carver Charitable Trust.
Address for reprint requests and other correspondence: S. R. Lentz, Dept. of Internal Medicine, C303 GH, The Univ. of Iowa, Iowa City, IA 52242 (E-mail: steven-lentz{at}uiowa.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 6 December 1999; accepted in final form 21 February 2000.
| |
REFERENCES |
|---|
|
|
|---|
1.
Bellamy, MF,
McDowell IFW,
Ramsey MW,
Brownlee M,
Bones C,
Newcombe RG,
and
Lewis MJ.
Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults.
Circulation
98:
1848-1852,
1998
2.
Bonthu, S,
Heistad DD,
Chappell DA,
Lamping KG,
and
Faraci FM.
Atherosclerosis, vascular remodeling, and impairment of endothelium-dependent relaxation in genetically altered hyperlipidemic mice.
Arterioscler Thromb Vasc Biol
17:
2333-2340,
1997
3.
Boushey, CJ,
Beresford SAA,
Omenn GS,
and
Motulsky AG.
A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes.
JAMA
274:
1049-1057,
1995
4.
Chambers, JC,
McGregor A,
Jean-Marie J,
and
Kooner JS.
Acute hyperhomocysteinemia and endothelial dysfunction.
Lancet
351:
36-37,
1998[Web of Science][Medline].
5.
Chambers, JC,
McGregor A,
Jean-Marie J,
Obeid OA,
and
Kooner JS.
Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia. An effect reversible with vitamin C therapy.
Circulation
99:
1156-1160,
1999
6.
Eberhardt, RT,
Forgione M,
Rudd MA,
Trolliet MR,
Cap A,
and
Loscalzo J.
Endothelial dysfunction in mice lacking the cystathionine
-synthase gene (Abstract).
Circulation
98:
I-44,
1998.
7.
Eikelboom, JW,
Lonn E,
Genest JJ,
Hankey G,
and
Yusuf S.
Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence.
Ann Intern Med
131:
363-375,
1999
8.
Faraci, FM,
Orgren K,
and
Heistad DD.
Impaired relaxation of the carotid artery during activation of ATP-sensitive potassium channels in atherosclerotic monkeys.
Stroke
25:
178-182,
1994[Abstract].
9.
Faraci, FM,
Sigmund CD,
Shesely EG,
Maeda N,
and
Heistad DD.
Responses of carotid artery in mice deficient in expression of the gene for endothelial NO synthase.
Am J Physiol Heart Circ Physiol
274:
H564-H570,
1998
10.
Finkelstein, JD.
The metabolism of homocysteine-pathways and regulation.
Eur J Pediatr
157:
S40-S44,
1998.
11.
Glaser, CB,
Morser J,
Clarke JH,
Blasko E,
McLean K,
Kuhn I,
Chang R-J,
Lin J-H,
Vilander L,
Andrews WH,
and
Light DR.
Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation.
J Clin Invest
90:
2565-2573,
1992.
12.
Guttormsen, AB,
Mansoor AM,
Fiskerstrand T,
Ueland PM,
and
Refsum H.
Kinetics of plasma homocysteine in healthy subjects after peroral homocysteine loading.
Clin Chem
39:
1390-1397,
1993[Abstract].
13.
Hajjar, KA,
Mauri L,
Jacovina AT,
Zhong FM,
Mirza UA,
Padovan JC,
and
Chait BT.
Tissue plasminogen activator binding to the annexin II tail domain-direct modulation by homocysteine.
J Biol Chem
273:
9987-9993,
1998
14.
Hayashi, T,
Honda G,
and
Suzuki K.
An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells.
Blood
79:
2930-2936,
1992
15.
Huang, PL,
Huang Z,
Mashimo H,
Bloch KD,
Moskowitz MA,
Bevan JA,
and
Fishman MC.
Hypertension in mice lacking the gene for endothelial nitric oxide synthase.
Nature
377:
239-242,
1995[Medline].
16.
Kanani, P,
Sinkey CA,
Browning RL,
Allaman M,
Knapp HR,
and
Haynes WG.
Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans.
Circulation
100:
1161-1168,
1999
17.
Kojda, G,
Laursen JB,
Ramasamy S,
Kent JD,
Kurz S,
Burchfield J,
Shesely EG,
and
Harrison DG.
Protein expression, vascular reactivity and soluble guanylate cyclase activity in mice lacking the endothelial cell nitric oxide synthase: contributions of NOS isoforms to blood pressure and heart rate control.
Cardiovasc Res
42:
206-213,
1999
18.
Lake-Bruse, KD,
Faraci FM,
Shesely EG,
Meada N,
and
Heistad DD.
Gene transfer of endothelial nitric oxide synthase (eNOS) in eNOS-deficient mice.
Am J Physiol Heart Circ Physiol
277:
H770-H776,
1999
19.
Lee, ME,
and
Wang H.
Homocysteine and hypomethylation-a novel link to vascular disease.
Trends Cardiovasc Med
9:
49-54,
1999[Web of Science][Medline].
20.
Lentz, SR.
Homocysteine and vascular dysfunction.
Life Sci
61:
1205-1215,
1997[Web of Science][Medline].
21.
Lentz, SR.
Mechanisms of thrombosis in hyperhomocysteinemia.
Curr Opin Hematol
5:
343-349,
1998[Medline].
22.
Lentz, SR,
Malinow MR,
Piegors DJ,
Bhopatkar-Teredesai M,
Faraci FM,
and
Heistad DD.
Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys.
Arterioscler Thromb Vasc Biol
17:
2930-2934,
1997
23.
Lentz, SR,
and
Sadler JE.
Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine.
J Clin Invest
88:
1906-1914,
1991.
24.
Lentz, SR,
and
Sadler JE.
The molecular basis of thrombomodulin function.
In: Thrombin, Thrombomodulin, and the Control of Hemostasis, edited by Giddings JC.. Austin, TX: Landes, 1994, p. 91-120.
25.
Lentz, SR,
Sobey CG,
Piegors DJ,
Bhopatkar MY,
Faraci FM,
Malinow MR,
and
Heistad DD.
Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia.
J Clin Invest
98:
24-29,
1996[Web of Science][Medline].
26.
Loscalzo, J.
The oxidant stress of hyperhomocyst(e)inemia.
J Clin Invest
98:
5-7,
1996[Web of Science][Medline].
27.
Malinow, MR,
Bostom AG,
and
Krauss RM.
Homocyst(e)ine, diet, and cardiovascular diseases-a statement for healthcare professionals from the Nutrition Committee, American Heart Association.
Circulation
99:
178-182,
1999
28.
Malinow, MR,
Kang SS,
Taylor LM,
Wong PWK,
Coull B,
Inahara T,
Mukerjee D,
Sexton G,
and
Upson B.
Prevalence of hyperhomocyt(e)inemia in patients with peripheral arterial occlusive disease.
Circulation
79:
1180-1188,
1989
29.
Malinow, MR,
Sexton G,
Averbuch M,
Grossman M,
Wilson D,
and
Upson B.
Homocyst(e)inemia in daily practice: levels in coronary artery disease.
Coron Artery Dis
1:
215-220,
1990.
30.
McCully, KS.
Homocysteine and vascular disease.
Nat Med
2:
386-389,
1996[Web of Science][Medline].
31.
Mudd, SH,
Levy HL,
and
Skovby F.
Disorders of transsulfuration.
In: The Metabolic and Molecular Basis of Inherited Disease, edited by Scriver CR,
Beaudet AL,
Sly WS,
and Valle D.. New York: McGraw-Hill, 1995, p. 1279-1327.
32.
Nygård, O,
Vollset SE,
Refsum H,
Brattstrom L,
and
Ueland PM.
Total homocysteine and cardiovascular disease.
J Int Med Res
246:
425-454,
1999.
33.
Outinen, PA,
Sood SK,
Pfeifer SI,
Pamidi S,
Podor TJ,
Li J,
Weitz JI,
and
Austin RC.
Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells.
Blood
94:
959-967,
1999
34.
Rodgers, GM,
and
Conn MT.
Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells.
Blood
75:
895-901,
1990
35.
Shaish, A,
George J,
Gilburd B,
Keren P,
Levkovitz H,
and
Harats D.
Dietary beta-carotene and alpha-tocopherol combination does not inhibit atherogenesis in an ApoE-deficient mouse model.
Arterioscler Thromb Vasc Biol
19:
1470-1475,
1999
36.
Stamler, JS,
Osborne JA,
Jaraki O,
Rabbani LE,
Mullins M,
Singel D,
and
Loscalzo J.
Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen.
J Clin Invest
91:
308-318,
1993.
37.
Upchurch, GR,
Welch GN,
Fabian AJ,
Freedman JE,
Johnson JL,
Keaney JF,
and
Loscalzo J.
Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase.
J Biol Chem
272:
17012-17017,
1997
38.
Usui, M,
Matsuoka H,
Miyazaki H,
Ueda S,
Okuda S,
and
Imaizumi T.
Endothelial dysfunction by acute hyperhomocyst(e)inemia: restoration by folic acid.
Clin Sci (Lond)
96:
235-239,
1999[Medline].
39.
Watanabe, M,
Osada J,
Aratani Y,
Kluckman K,
Reddick R,
Malinow MR,
and
Maeda N.
Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia.
Proc Natl Acad Sci USA
92:
1585-1589,
1995
This article has been cited by other articles:
![]() |
T. Kitami, R. Rubio, W. O'Brien, J. Quackenbush, and J. H. Nadeau Gene-environment interactions reveal a homeostatic role for cholesterol metabolism during dietary folate perturbation in mice Physiol Genomics, October 8, 2008; 35(2): 182 - 190. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dayal and S. R. Lentz Murine Models of Hyperhomocysteinemia and Their Vascular Phenotypes Arterioscler Thromb Vasc Biol, September 1, 2008; 28(9): 1596 - 1605. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dayal, R. N. Rodionov, E. Arning, T. Bottiglieri, M. Kimoto, D. J. Murry, J. P. Cooke, F. M. Faraci, and S. R. Lentz Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H816 - H825. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Looft-Wilson, B. S. Ashley, J. E. Billig, M. R. Wolfert, L. A. Ambrecht, and S. E. Bearden Chronic diet-induced hyperhomocysteinemia impairs eNOS regulation in mouse mesenteric arteries Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R59 - R66. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Sontag, V. Nunbhakdi-Craig, J.-M. Sontag, R. Diaz-Arrastia, E. Ogris, S. Dayal, S. R. Lentz, E. Arning, and T. Bottiglieri Protein Phosphatase 2A Methyltransferase Links Homocysteine Metabolism with Tau and Amyloid Precursor Protein Regulation J. Neurosci., March 14, 2007; 27(11): 2751 - 2759. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Symons, J. C. Rutledge, U. Simonsen, and R. A. Pattathu Vascular dysfunction produced by hyperhomocysteinemia is more severe in the presence of low folate Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H181 - H191. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. Powers, R. E. Gandley, D. L. Lykins, and J. M. Roberts Moderate Hyperhomocysteinemia Decreases Endothelial-Dependent Vasorelaxation in Pregnant But Not Nonpregnant Mice Hypertension, September 1, 2004; 44(3): 327 - 333. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Vitvitsky, S. Dayal, S. Stabler, Y. Zhou, H. Wang, S. R. Lentz, and R. Banerjee Perturbations in homocysteine-linked redox homeostasis in a murine model for hyperhomocysteinemia Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2004; 287(1): R39 - R46. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zulli, R. E. Widdop, D. L. Hare, B. F. Buxton, and M. J. Black High Methionine and Cholesterol Diet Abolishes Endothelial Relaxation Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1358 - 1363. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Robert, F. Vialard, E. Thiery, K. Toyama, P.-M. Sinet, N. Janel, and J. London Expression of the Cystathionine {beta} Synthase (CBS) Gene During Mouse Development and Immunolocalization in Adult Brain J. Histochem. Cytochem., March 1, 2003; 51(3): 363 - 371. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. M. Faraci Hyperhomocysteinemia: A Million Ways to Lose Control Arterioscler Thromb Vasc Biol, March 1, 2003; 23(3): 371 - 373. [Full Text] [PDF] |
||||
![]() |
H. S. Sood, M. J. Hunt, and S. C. Tyagi Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia Am J Physiol Lung Cell Mol Physiol, February 1, 2003; 284(2): L333 - L341. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ratnam, K. N. Maclean, R. L. Jacobs, M. E. Brosnan, J. P. Kraus, and J. T. Brosnan Hormonal Regulation of Cystathionine beta -Synthase Expression in Liver J. Biol. Chem., November 1, 2002; 277(45): 42912 - 42918. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Weiss, C. Keller, U. Hoffmann, and J. Loscalzo Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia Vascular Medicine, August 1, 2002; 7(3): 227 - 239. [Abstract] [PDF] |
||||
![]() |
S. F. Choumenkovitch, J. Selhub, P. J. Bagley, N. Maeda, M. R. Nadeau, D. E. Smith, and S.-W. Choi In the Cystathionine {beta}-Synthase Knockout Mouse, Elevations in Total Plasma Homocysteine Increase Tissue S-Adenosylhomocysteine, but Responses of S-Adenosylmethionine and DNA Methylation Are Tissue Specific J. Nutr., August 1, 2002; 132(8): 2157 - 2160. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Symons, A. E. Mullick, J. L. Ensunsa, A. A. Ma, and J. C. Rutledge Hyperhomocysteinemia Evoked by Folate Depletion: Effects on Coronary and Carotid Arterial Function Arterioscler Thromb Vasc Biol, May 1, 2002; 22(5): 772 - 780. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhou, J. Moller, C. C. Danielsen, J. Bentzon, H. B. Ravn, R. C. Austin, and E. Falk Dietary Supplementation With Methionine and Homocysteine Promotes Early Atherosclerosis but Not Plaque Rupture in ApoE-Deficient Mice Arterioscler Thromb Vasc Biol, September 1, 2001; 21(9): 1470 - 1476. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Weiss, Y.-Y. Zhang, S. Heydrick, C. Bierl, and J. Loscalzo Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction PNAS, October 23, 2001; 98(22): 12503 - 12508. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |